Breaking News Instant updates and real-time market news.

SGMO

Sangamo

$4.60

0.27 (6.24%)

, EDIT

Editas Medicine

$14.51

0.45 (3.20%)

07:55
10/11/16
10/11
07:55
10/11/16
07:55

Jefferies to hold a summit

Gene Editing/Therapy Summit to be held in New York on October 11.

SGMO

Sangamo

$4.60

0.27 (6.24%)

EDIT

Editas Medicine

$14.51

0.45 (3.20%)

NTLA

Intellia Therapeutics

$14.44

-0.66 (-4.37%)

BOLD

Audentes Therapeutics

$18.34

-0.09 (-0.49%)

RGNX

REGENXBIO

$17.82

1.63 (10.07%)

ABEO

Abeona Therapeutics

$6.86

0.07 (1.03%)

ONCE

Spark Therapeutics

$63.18

1.84 (3.00%)

  • 11

    Oct

  • 12

    Oct

  • 06

    Nov

SGMO Sangamo
$4.60

0.27 (6.24%)

08/04/16
JANY
08/04/16
DOWNGRADE
JANY
Neutral
Sangamo downgraded to Neutral from Buy at Janney Capital
09/06/16
WELS
09/06/16
NO CHANGE
WELS
Outperform
Wells calls Sangamo an 'attractive new investment opportunity'
After the FDA granted orphan drug designation to its Factor IX gene-editing product candidate, SB-FIX, as a treatment for hemophilia B, Wells Fargo analyst Jim Birchenough calls Sangamo BioSciences an "attractive new investment opportunity." Along with validating a commercial opportunity in hemophilia, SB-FIX could provide "even more valuable validation of targeting and coopting the albumin gene locus for gene insertion that may apply to a wide variety of genetic diseases," Birchenough tells investors in a research note. He keeps an Outperform rating on the shares.
12/17/15
12/17/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ADP (ADP) initiated with a Neutral at Sterne Agee CRT... Accenture (ACN) initiated with a Buy at Sterne Agee CRT... Alliance Data (ADS) initiated with a Buy at Sterne Agee CRT... Axsome Therapies (AXSM) initiated with a Buy at Brean Capital... Blue Bird (BLBD) initiated with a Buy at Stifel... Burlington Stores (BURL) initiated with a Hold at BB&T... Chimerix (CMRX) initiated with a Buy at UBS... Cimarex Energy (XEC) initiated with a Buy at SunTrust... Clovis (CLVS) initiated with a Buy at Janney Capital... Cognizant (CTSH) initiated with a Neutral at Sterne Agee CRT... Container Store (TCS) initiated with a Neutral at Goldman... Cooper Companies (COO) initiated with a Neutral at Goldman... Corcept Therapeutics (CORT) initiated with a Buy at Janney Capital... Dave & Buster's (PLAY) initiated with an Outperform at BMO Capital... EPAM Systems (EPAM) initiated with a Buy at Sterne Agee CRT... FIS (FIS) initiated with a Neutral at Sterne Agee CRT... First Data (FDC) initiated with a Buy at Sterne Agee CRT... Fiserv (FISV) initiated with a Buy at Sterne Agee CRT... Frontline (FRO) initiated with a Buy at Seaport Global... Gener8 Maritime (GNRT) initiated with a Buy at Seaport Global... Genocea (GNCA) initiated with a Buy at UBS... Geron (GERN) initiated with a Buy at Janney Capital... Global Payments (GPN) initiated with a Buy at Sterne Agee CRT... Globant (GLOB) initiated with a Buy at Sterne Agee CRT... Harris (HRS) initiated with a Buy at Jefferies... Horizon Pharma (HZNP) initiated with a Buy at Goldman... Infosys (INFY) initiated with a Neutral at Sterne Agee CRT... Kate Spade (KATE) initiated with a Neutral at Goldman... Marinus Pharmaceuticals (MRNS) initiated with an Outperform at RBC Capital... MasterCard (MA) initiated with a Buy at Sterne Agee CRT... MicroVision (MVIS) initiated with a Buy at Rodman & Renshaw... Monro Muffler (MNRO) initiated with a Neutral at Goldman... Newfield Exploration (NFX) initiated with a Neutral at SunTrust... Orbital ATK (OA) initiated with a Buy at UBS... Paychex (PAYX) initiated with a Neutral at Sterne Agee CRT... Relypsa (RLYP) initiated with a Buy at H.C. Wainwright... Republic Services (RSG) initiated with an Overweight at JPMorgan... Ross Stores (ROST) initiated with a Buy at BB&T... Rubicon Project (RUBI) initiated with a Buy at Jefferies... Sangamo (SGMO) initiated with a Buy at Janney Capital... Skyworks (SWKS) initiated with a Buy at Chardan... TJX (TJX) initiated with a Buy at BB&T... TopBuild (BLD) initiated with an Overweight at Stephens... Unit Corp. (UNT) initiated with a Buy at SunTrust... Upland Software (UPLD) initiated with a Buy at Roth Capital... Virtusa (VRTU) initiated with a Neutral at Sterne Agee CRT... Visa (V) initiated with a Buy at Sterne Agee CRT... Waste Connections (WCN) initiated with an Overweight at JPMorgan... Waste Management (WM) initiated with a Neutral at JPMorgan... Williams-Sonoma (WSM) initiated with a Neutral at Guggenheim... Wipro (WIT) initiated with an Underperform at Sterne Agee CRT... vTv Therapeutics (VTVT) initiated with a Buy at Janney Capital.
03/07/16
JANY
03/07/16
NO CHANGE
Target $15
JANY
Buy
Sangamo data support expectations for IVPRP efficacy, says Janney Capital
Janney Capital analyst Roy Buchanan says that updated mouse data for Sangamo's in vivo protein replacement platform, or IVPRP, for treating MPS I and II continue to support expectations for efficacy and that the brain data is encouraging and adds additional support. The analyst notes, however, that he hasn't increased his probability of success for the program on this data, as much of it had been presented previously. Buchanan keeps a Buy rating and $15 fair value estimate on Sangamo shares.
EDIT Editas Medicine
$14.51

0.45 (3.20%)

08/10/16
JEFF
08/10/16
UPGRADE
Target $35
JEFF
Buy
Editas Medicine upgraded to Buy from Hold at Jefferies
Jefferies analyst Gena Wang upgraded Editas Medicine to Buy saying the recent pullback in the shares provides an opportunity to own the company's "transformative CRIPSR technology." The analyst keeps a $35 price target for the shares.
06/21/16
JANY
06/21/16
NO CHANGE
Target $48
JANY
Buy
Janney says Editas may be weak after UPenn scientists first to Cas9 RAC
Janney Capital analyst Roy Buchanan noted that members of the NIH's Recombinant DNA Advisory Committee, or RAC, were supportive of a phase 1 trial proposed by scientists at the University of Pennsylvania to test the use of CRISPR-Cas9 to create genetically altered immune cells to attack cancer. Buchanan noted shares of Editas Medicine may be impacted since the company will not be the first to the Cas9 RAC, as had been expected, but he noted this academic study will address a limited patient population, adding that "there is plenty of CAR-T/TCR space left to operate". The firm has a Buy rating and $48 fair value estimate on Editas shares.
06/02/16
JEFF
06/02/16
INITIATION
Target $35
JEFF
Hold
Editas Medicine initiated with a Hold at Jefferies
Jefferies analyst Gena Wang started Editas Medicine with a Hold rating and $35 price target.
02/29/16
02/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Brian Ossenbeck initiated a cautious outlook for the North American truckload sector, saying he believes "tepid" freight demand and a lack of a boost to consumer spending from low gas prices will lead the first contraction in realized revenue per loaded mile since 2007. Ossenteck initiated Werner (WERN) with an Overweight rating due to expectations that its diversification will drive a re-rating of its shares. The analyst set a Neutral rating on Swift Transport (SWFT) and Ryder (R), and an Underweight rating on Heartland Express (HTLD) and Knight Transportation (KNX). 2. Editas Medicine (EDIT) initiated with an Outperform at Cowen and JMP Securities, and a Neutral at JPMorgan. Cowen cited the company's "world-class expertise" in CRISPR, which will enable the development of a broad pipeline. JPMorgan analyst Cory Kasimov added that the company's CRISPR gene editing platform has the potential to be a game changer, but that it has "limited value-inflecting news" likely to come in 2016. 3. BeiGene (BGNE) initiated with an Outperform at Cowen citing the proof-of-concept data on each of four clinical candidates and expects to monetize those assets on the global stage. The company was also initiated with an Overweight and a Buy at Morgan Stanley and Goldman, respectively. 4. Nielsen (NLSN) initiated with a Buy at Jefferies by analyst Ryan Cary, who said the company is well positioned to benefit from demand for cross-platform viewership measurement and greenfield in emerging markets provides protection against macro headwinds. 5. Square (SQ) initiated with a Sector Weight at Pacific Crest by analyst Josh Beck, who said his optimism is balanced by the market's high expectations for execution, the uncertain regulatory environment for SMB lending, and software initiatives. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
NTLA Intellia Therapeutics
$14.44

-0.66 (-4.37%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
08/05/16
LEER
08/05/16
UPGRADE
Target $32
LEER
Outperform
Intellia Therapeutics upgraded to Outperform from Market Perform at Leerink
Leerink analyst Michael Schmidt upgraded Intellia Therapeutics to Outperform from Market Perform on valuation. The analyst believes the stock's current valuation represents an attractive entry point to own "one of the most exciting" technology platforms Biotech has to offer. Schmidt says Intellia Therapeutics is a leader in the development of CRISPR/Cas9-based genome editing therapeutics, and believes its platform has disruptive potential that could expand the potential of existing genome therapeutics. He has a $32 price target on the shares.
09/28/16
JANY
09/28/16
INITIATION
Target $29
JANY
Buy
Intellia Therapeutics initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Intellia Therapeutics with a Buy and a $29 fair value estimate.
08/05/16
JEFF
08/05/16
UPGRADE
Target $33
JEFF
Buy
Intellia Therapeutics upgraded to Buy from Hold at Jefferies
Jefferies analyst Gena Wang upgraded Intellia Therapeutics to Buy following the company's Q2 results. The company has "transformative" gene-editing technology and has enough cash to support operation through 2020, Wang tells investors in a post-earnings research note. The analyst keeps a $33 price target for the shares.
BOLD Audentes Therapeutics
$18.34

-0.09 (-0.49%)

08/15/16
WEDB
08/15/16
INITIATION
Target $20
WEDB
Outperform
Audentes Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated Audentes Therapeutics with an Outperform and $20 price target saying its a compelling opportunity in AAV gene therapy of rare diseases.
08/15/16
COWN
08/15/16
INITIATION
COWN
Outperform
Audentes Therapeutics initiated with an Outperform at Cowen
Cowen analyst Ritu Baral started Audentes Therapeutics with an Outperform rating.
08/15/16
PIPR
08/15/16
INITIATION
Target $24
PIPR
Overweight
Audentes Therapeutics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer started Audentes Therapeutics with an Overweight rating and $24 price target. The analyst views the company as well-positioned in the "rapidly evolving gene therapy landscape."
10/10/16
PIPR
10/10/16
NO CHANGE
Target $24
PIPR
Overweight
AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.
RGNX REGENXBIO
$17.82

1.63 (10.07%)

10/20/15
CHDN
10/20/15
INITIATION
Target $33
CHDN
Buy
Regenxbio initiated with a Buy at Chardan
Target $33.
01/07/16
PIPR
01/07/16
NO CHANGE
Target $33
PIPR
Overweight
REGENXBIO pipeline expanding faster than expected, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said REGENXBIO's corporate updates released this morning show that its preclinical pipeline is expanding faster than he'd expected. The analyst continues to think that this year will include relevant newsflow for REGENXBIO as the company's vectors progress toward clinical development and keeps an Overweight rating on shares, but trimmed his price target to $33 from $36 to account for the company's guidance for a 2016 cash burn of $60M-$70M.
12/30/15
CHDN
12/30/15
NO CHANGE
Target $35
CHDN
Buy
REGENXBIO news a clear positive, says Chardan
Chardan analyst Gbolahan Amusa raised his price target for REGENXBIO shares to $35 from $33 after the FDA granted Rare Pediatric Disease Designation to RGX-111, the company's investigational gene therapy product candidate for the treatment of mucopolysaccharidosis Type I. The designation could lead to a Rare Pediatric Disease Priority Review Voucher, which could be worth up to $8 per share, Amusa tells investors in a research note. The analyst keeps a Buy rating on the stock.
10/20/15
10/20/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 21st Century Fox (FOXA) initiated with a Buy at Pivotal Research... AMC Networks (AMCX) initiated with a Market Perform at Cowen... Aduro Biotech (ADRO) initiated with an Outperform at Oppenheimer... CBS (CBS) initiated with a Buy at Pivotal Research... CDTi (CDTI) initiated with a Buy at Rodman & Renshaw... Callon Petroleum (CPE) initiated with a Buy at Canaccord... Cimarex Energy (XEC) initiated with a Hold at Canaccord... Cooper Tire (CTB) initiated with a Hold at Jefferies... Cubic (CUB) initiated with a Buy at BB&T... Diamond Offshore (DO) initiated with a Sell at Citi... Diamondback Energy (FANG) initiated with a Buy at Canaccord... Discovery (DISCA) initiated with a Buy at Pivotal Research... Disney (DIS) initiated with a Hold at Pivotal Research... Dorman Products (DORM) initiated with a Hold at Jefferies... Ensco (ESV) initiated with a Buy at Citi... First Data (FDC) initiated with a Positive at Susquehanna... InterOil (IOC) initiated with a Buy at Citi... Matador (MTDR) initiated with a Hold at Canaccord... Monro Muffler (MNRO) initiated with a Buy at Sterne Agee CRT... Noble Corp. (NE) initiated with a Neutral at Citi... Pacific Drilling (PACD) initiated with a Neutral at Citi... Parsley Energy (PE) initiated with a Buy at Canaccord... Pioneer Natural (PXD) initiated with a Buy at Canaccord... Pure Storage (PSTG) initiated with a Hold at Jefferies... Qorvo (QRVO) initiated with a Buy at Drexel Hamilton... RSP Permian (RSPP) initiated with a Hold at Canaccord... Regenxbio (RGNX) initiated with a Buy at Chardan... Reliance Steel (RS) initiated with a Buy at Deutsche Bank... Resonant (RESN) initiated with a Buy at Drexel Hamilton... Ring Energy (REI) initiated with a Buy at Canaccord... Rock Creek Pharmaceuticals (RCPI) initiated with a Buy at Maxim... Rowan Companies (RDC) initiated with a Neutral at Citi... Shire (SHPG) initiated with a Buy at BTIG... Skyworks (SWKS) initiated with a Buy at Drexel Hamilton... Snap-On (SNA) initiated with a Hold at Jefferies... Standard Motor (SMP) initiated with a Buy at Jefferies... Time Warner (TWX) initiated with a Buy at Pivotal Research... TowerJazz (TSEM) initiated with a Buy at Drexel Hamilton... Transocean (RIG) initiated with a Sell at Citi... Viacom (VIAB) initiated with a Buy at Pivotal Research... bluebird bio (BLUE) initiated with an Outperform at Oppenheimer.
ABEO Abeona Therapeutics
$6.86

0.07 (1.03%)

09/07/16
CANT
09/07/16
INITIATION
Target $21
CANT
Buy
Abeona Therapeutics initiated with a Buy at Cantor
Cantor initiated Abeona Therapeutics with a Buy and $21 price target.
09/21/16
MAXM
09/21/16
NO CHANGE
Target $8
MAXM
Buy
Abeona Therapeutics price target raised to $8 from $6 at Maxim
Maxim raised Buy rated Abeona's price target to $8 from $6 following news the company has licensed a next-generation AAV gene therapy platform from the University of North Carolina that may make gene therapy available to patients with CNS disorders who have immune responses against natural AAV vectors used in first-generation AAV gene therapies currently in development.
09/29/16
MAXM
09/29/16
NO CHANGE
Target $14
MAXM
Buy
Abeona Therapeutics price target raised to $14 from $8 at Maxim
Maxim analyst Jason McCarthy raised Abeona's price target to $14 from $8 saying he expects multiple data points across several gene therapy programs to potentially push shares higher. The analyst said clinical development is underway in Abeona's Sanfilippo with positive data in two patients so far, and data from more patients are expected this fall. The company is also advancing a second Sanfilippo gene therapy, ABO-101, into the clinic later this year. Also, Abeona has brought on board a more advanced gene therapy from Stanford University, EB-101, to treat a rare skin disease which demonstrated positive data in five patients and has advanced to phase II, McCarthy wrote.
12/16/15
12/16/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abeona Therapeutics (ABEO) initiated with a Buy at Maxim... Accelerate Diagnostics (AXDX) initiated with an Overweight at Piper Jaffray... Aetna (AET) initiated with a Neutral at Credit Suisse... Agenus (AGEN) initiated with a Buy at Jefferies... Apple Hospitality REIT (APLE) initiated with a Buy at Canaccord... Brunswick (BC) initiated with an Overweight at JPMorgan... Carlisle (CSL) initiated with a Buy at Wunderlich... Castlight Health (CSLT) initiated with a Buy at Topeka... Centene (CNC) initiated with an Outperform at Credit Suisse... ConAgra (CAG) initiated with a Buy at Jefferies... Dean Foods (DF) initiated with a Buy at Jefferies... First Merchants (FRME) initiated with a Neutral at SunTrust... Flowers Foods (FLO) initiated with a Buy at Jefferies... Glatfelter (GLT) initiated with a Buy at Sidoti... HCA Holdings (HCA) initiated with an Outperform at Credit Suisse... Hain Celestial (HAIN) assumed with a Buy at Jefferies... Hormel Foods (HRL) initiated with a Buy at Jefferies... Humana (HUM) initiated with a Neutral at Credit Suisse... Ingredion (INGR) initiated with a Buy at Jefferies... J & J Snack Foods (JJSF) initiated with a Hold at Jefferies... J.M. Smucker (SJM) initiated with a Buy at Jefferies... Kura Oncology (KURA) initiated with a Buy at Citi... LifePoint (LPNT) initiated with an Outperform at Credit Suisse... MasterCard (MA) initiated with a Buy at UBS... Matador (MTDR) initiated with a Neutral at BofA/Merrill... McCormick (MKC) initiated with a Hold at Jefferies... Molina Healthcare (MOH) initiated with a Neutral at Credit Suisse... NetApp (NTAP) initiated with an Underperform at JMP Securities... Nimble Storage (NMBL) initiated with a Market Perform at JMP Securities... Pilgrim's Pride (PPC) initiated with a Hold at Jefferies... Pure Storage (PSTG) initiated with an Outperform at JMP Securities... Rexford Industrial (REXR) initiated with a Buy at Stifel... Rice Energy (RICE) initiated with a Hold at Deutsche Bank... Sanderson Farms (SAFM) initiated with an Underperform at Jefferies... Snyder's-Lance (LNCE) initiated with a Buy at Jefferies... SodaStream (SODA) initiated with a Hold at Jefferies... Tenet (THC) initiated with a Neutral at Credit Suisse... TreeHouse (THS) initiated with a Buy at Jefferies... Tyson Foods (TSN) initiated with a Buy at Jefferies... UnitedHealth (UNH) initiated with an Outperform at Credit Suisse... Universal Health (UHS) initiated with a Neutral at Credit Suisse... Varonis (VRNS) initiated with a Buy at Lake Street... Visa (V) initiated with a Buy at UBS... WellCare (WCG) initiated with an Underperform at Credit Suisse... WhiteWave (WWAV) initiated with a Buy at Jefferies... aTyr Pharma (LIFE) initiated with a Neutral at Citi.
ONCE Spark Therapeutics
$63.18

1.84 (3.00%)

09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
09/02/16
STFL
09/02/16
INITIATION
STFL
Buy
Spark Therapeutics initiated with a Buy at Stifel
Target $73.

TODAY'S FREE FLY STORIES

SONC

Sonic

$25.47

-0.02 (-0.08%)

14:52
12/06/16
12/06
14:52
12/06/16
14:52
Conference/Events
Sonic management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

SFTBF

SoftBank

$60.07

-0.15 (-0.25%)

, S

Sprint

$8.25

0.195 (2.42%)

14:50
12/06/16
12/06
14:50
12/06/16
14:50
Periodicals
Breaking Periodicals news story on SoftBank, Sprint, T-Mobile »

SoftBank's Son…

SFTBF

SoftBank

$60.07

-0.15 (-0.25%)

S

Sprint

$8.25

0.195 (2.42%)

TMUS

T-Mobile

$55.02

0.58 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Dec

  • 04

    Jan

CRHM

CRH Medical

$5.45

-0.2 (-3.54%)

14:50
12/06/16
12/06
14:50
12/06/16
14:50
Conference/Events
CRH Medical management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PLAY

Dave & Buster's

$48.83

1.29 (2.71%)

14:49
12/06/16
12/06
14:49
12/06/16
14:49
Options
Dave & Buster's options imply 9.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 09

    Jan

  • 09

    Jan

RHHBY

Roche

$27.67

0.47 (1.73%)

14:46
12/06/16
12/06
14:46
12/06/16
14:46
Hot Stocks
Genentech says FDA approves Avastin for treatment of type of ovarian cancer »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$762.52

12.02 (1.60%)

, GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

14:46
12/06/16
12/06
14:46
12/06/16
14:46
Hot Stocks
YouTube says paid out over $1B to music industry in past year »

Alphabet's (GOOG)…

GOOG

Alphabet

$762.52

12.02 (1.60%)

GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

SNE

Sony

$28.19

0.045 (0.16%)

VIVHY

Vivendi

$18.98

0.225 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

S

Sprint

$8.22

0.17 (2.11%)

14:45
12/06/16
12/06
14:45
12/06/16
14:45
Options
Sprint call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 04

    Jan

PBIB

Porter Bancorp

$2.03

-0.44 (-17.81%)

14:44
12/06/16
12/06
14:44
12/06/16
14:44
Hot Stocks
Breaking Hot Stocks news story on Porter Bancorp »

Seidman reports 9.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$77.24

0.53 (0.69%)

, CAKE

Cheesecake Factory

$61.40

0.92 (1.52%)

14:37
12/06/16
12/06
14:37
12/06/16
14:37
Hot Stocks
NPD says Q3 foodservice visits fall 1%, quick service restaurant traffic drops »

Market researcher NPD…

DRI

Darden

$77.24

0.53 (0.69%)

CAKE

Cheesecake Factory

$61.40

0.92 (1.52%)

CMG

Chipotle

$368.42

-27.8522 (-7.03%)

YUM

Yum! Brands

$63.41

0.35 (0.56%)

PNRA

Panera Bread

$213.51

-0.16 (-0.07%)

JACK

Jack in the Box

$108.24

1.09 (1.02%)

MCD

McDonald's

$119.04

-0.25 (-0.21%)

DPZ

Domino's Pizza

$167.99

1.7 (1.02%)

QSR

Restaurant Brands

$48.14

0.05 (0.10%)

WEN

Wendy's

$12.85

0.23 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 20

    Dec

  • 09

    Jan

VRA

Vera Bradley

$14.74

0.67 (4.76%)

14:32
12/06/16
12/06
14:32
12/06/16
14:32
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PLAY

Dave & Buster's

$48.83

1.29 (2.71%)

, AVAV

AeroVironment

$28.58

0.58 (2.07%)

14:31
12/06/16
12/06
14:31
12/06/16
14:31
Earnings
Notable companies reporting after market close »

Notable companies…

PLAY

Dave & Buster's

$48.83

1.29 (2.71%)

AVAV

AeroVironment

$28.58

0.58 (2.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 09

    Jan

  • 09

    Jan

HLT

Hilton

$26.31

0.22 (0.84%)

14:25
12/06/16
12/06
14:25
12/06/16
14:25
Options
Hilton call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

14:25
12/06/16
12/06
14:25
12/06/16
14:25
General news
Masayoshi Son of Softbank agreed to $50 B investment in the U.S. »

Masayoshi Son of Softbank…

14:20
12/06/16
12/06
14:20
12/06/16
14:20
General news
Treasury Option Action: put buying at the long end »

Treasury Option Action:…

14:18
12/06/16
12/06
14:18
12/06/16
14:18
General news
Averages at best levels of day in afternoon trading »

Stocks have taken a leg…

IL

Intralinks

$13.22

1.95 (17.30%)

14:18
12/06/16
12/06
14:18
12/06/16
14:18
Downgrade
Intralinks rating change  »

Intralinks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

S

Sprint

$7.96

-0.09 (-1.12%)

, TMUS

T-Mobile

$55.02

0.58 (1.07%)

14:17
12/06/16
12/06
14:17
12/06/16
14:17
Hot Stocks
Breaking Hot Stocks news story on Sprint, T-Mobile, SoftBank »

Sprint, T-Mobile shares…

S

Sprint

$7.96

-0.09 (-1.12%)

TMUS

T-Mobile

$55.02

0.58 (1.07%)

SFTBF

SoftBank

$60.07

-0.15 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Dec

  • 04

    Jan

SFTBF

SoftBank

$60.07

-0.15 (-0.25%)

14:16
12/06/16
12/06
14:16
12/06/16
14:16
Hot Stocks
Trump says SoftBank has agreed to invest $50B in U.S. »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
12/06/16
12/06
14:16
12/06/16
14:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:16
12/06/16
12/06
14:16
12/06/16
14:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavier than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BF.B

Brown Forman, also tag with BFA, BFB

$44.91

-0.17 (-0.38%)

, BFB

Brown-Forman, also tag with BF.A, BF.B

14:14
12/06/16
12/06
14:14
12/06/16
14:14
Technical Analysis
Brown-Forman technical notes ahead of earnings news »

The shares have just…

BF.B

Brown Forman, also tag with BFA, BFB

$44.91

-0.17 (-0.38%)

BFB

Brown-Forman, also tag with BF.A, BF.B

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ALK

Alaska Air

$83.91

0.79 (0.95%)

, VA

Virgin America

$56.45

-0.1 (-0.18%)

14:10
12/06/16
12/06
14:10
12/06/16
14:10
Hot Stocks
Breaking Hot Stocks news story on Alaska Air, Virgin America »

Alaska Air 'remains…

ALK

Alaska Air

$83.91

0.79 (0.95%)

VA

Virgin America

$56.45

-0.1 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$83.92

0.8 (0.96%)

, VA

Virgin America

$56.45

-0.1 (-0.18%)

14:09
12/06/16
12/06
14:09
12/06/16
14:09
Hot Stocks
Breaking Hot Stocks news story on Alaska Air, Virgin America »

Alaska Air sees…

ALK

Alaska Air

$83.92

0.8 (0.96%)

VA

Virgin America

$56.45

-0.1 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$83.95

0.83 (1.00%)

, VA

Virgin America

$56.45

-0.1 (-0.18%)

14:07
12/06/16
12/06
14:07
12/06/16
14:07
Hot Stocks
Alaska Air says codeshare today is smaller part of revenue »

Alaska Air says codeshare…

ALK

Alaska Air

$83.95

0.83 (1.00%)

VA

Virgin America

$56.45

-0.1 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$83.95

0.83 (1.00%)

, VA

Virgin America

$56.45

-0.1 (-0.18%)

14:05
12/06/16
12/06
14:05
12/06/16
14:05
Hot Stocks
Alaska Air sees financial impact of codeshare reduction $15M-$20M »

"There are 45…

ALK

Alaska Air

$83.95

0.83 (1.00%)

VA

Virgin America

$56.45

-0.1 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.